Eribulin drug review
Eribulin is an anticancer drug approved for treatment of metastatic breast cancer. This drug is a synthetic derivative from Japanese marine sponge Halichondria okadai. It acts by interfering with the microtubular growth ultimately leading to apoptosis after prolonged mitotic blockage. In patients wi...
Main Authors: | Nishitha Shetty, Sudeep Gupta |
---|---|
Format: | Article |
Language: | English |
Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2014-01-01
|
Series: | South Asian Journal of Cancer |
Subjects: | |
Online Access: | http://journal.sajc.org/article.asp?issn=2278-330X;year=2014;volume=3;issue=1;spage=57;epage=59;aulast=Shetty |
Similar Items
-
The role of capecitabine and eribulin in the treatment of metastatic HER2-negative metastatic breast cancer
by: I V Kolyadina, et al.
Published: (2018-09-01) -
Eribulin for the treatment of anthracyclineand taxane-resistant breast cancer: a big step forward towards problem solving
by: E V Artamonova
Published: (2017-09-01) -
Advances in the treatment of soft tissue sarcoma: focus on eribulin
by: Koliou P, et al.
Published: (2018-02-01) -
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia
by: Vera A Gorbunova, et al.
Published: (2019-03-01) -
Eribulin and Confusion: A Previously Unknown Drug Side-Effect
by: Abu Baker Sheikh, et al.
Published: (2020-06-01)